ClinicalTrials.gg
WithdrawnNCT04757246RESPECTUpdated Oct 24, 2022

RESPECT Heart Failure- RESpiratory Pattern Evaluation in Clinical Trials for HF

An interventional study of MouthLab Device in Heart Failure, sponsored by WakeMed Health and Hospitals. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by WakeMed Health and Hospitals · Not applicable, Interventional, and Other

How we know

Why this study was withdrawn
Funding from Sponsor did not come through

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
1,523rd of 1,602
0 · median 66
Started
2022
with 106 others
No phase
887 of 2,159
159 open now
Registered
1,551st of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 1,523rd largest by enrollment of the 1,602 interventional ones that give a count, is one of 107 that started in 2022, is one of 887 with no phase, and was the 1,551st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The goal is to evaluate the trends in MouthLab parameters (respiration rate, temperature, pulse rate, electrocardiogram rhythm, blood pressure, oxygen saturation heart rate and basic lung function measures) in patients with decompensated heart failure and how these measurements change in response to decongestion. The research will test the ability of the MouthLab device to predict clinical decompensation in patients with known heart failure and to reduce the number of hospital readmissions based on the treatment guided by MouthLab device data.

Read the detailed description

Heart failure (HF) is becoming increasingly recognized with an estimated worldwide prevalence of >37.7 million individuals. In the United States alone, there are over 5 million patients with HF which is expected to increase to over 8 million by 2030. Despite advances in medical therapies and technology, HF remains the leading cause of hospitalization among adults and the elderly. By 2030, the medical costs of HF are expected to rise from $20.9 billion to $53.1 billion, with nearly 80% of the projected increased expenses attributes to hospitalization costs. As such, it is imperative to develop new technologies and treatment options to impact the HF epidemic.

The majority of HF hospital admissions are due to volume overload. Stiffened and/or weakened myocardium predisposes patients to the accumulation of extracellular fluid resulting in increased intracardiac filling pressures and symptoms of congestion (edema, dyspnea and orthopnea). Accurate assessment of a patient's volume status remains clinically challenging at times. While there have been technological advances in the outpatient monitoring of volume status through thoracic impedance and pulmonary artery pressure monitoring, there are no validated, non-implantable options for monitoring volume status outside of the physical exam.

Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple medical parameters such as - Temperature, Blood Pressure, Heart Rate, Heart Rate Variability, Pulse Rate, SpO2, single-lead ECG, Respiratory Rate, Breathing Pattern/Respiratory Flow Cycle Morphology, and basic lung functions (FEV1, FVC, FEV1/FVC, PEF) in 30 seconds.

The investigators believe that the MouthLab device holds the potential to identify changes in volume status through measurements such as pulse rate, oxygen saturation, respiratory flow and lung function and accurately predict decompensation in patients with chronic HF. The investigators propose the following outline of clinical studies to evaluate the utility of the MouthLab device in HF.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inpatient Sub-Study Eligibility Criteria

Inclusion Criteria

  1. Adults aged ≥ 18 years old
  2. Willing and able to provide
  3. Admitted within previous 24 hours with HF exacerbation requiring intravenous diuretic therapy (reduced or preserved )
  4. English speaking

Exclusion Criteria

  1. Currently on dialysis
  2. Patients with acute coronary syndrome
  3. Currently on hospice
  4. Have a heart transplant or left ventricular assist device

    • Outpatient Sub-Study Eligibility Criteria

Inclusion Criteria

  1. Adults aged ≥ 18 years old
  2. Willing and able to provide informed consent
  3. Patients presenting to the clinic and not being admitted to the hospital, who have been admitted for a HF exacerbation within the past 6 months, OR patients being discharged from a HF exacerbation related inpatient hospitalization
  4. For inclusion in Cohort 2, patients must have Boston Scientific pacemaker or defibrillator with Heart Logic capability
  5. For inclusion in Cohort 3, patients must have implantable CardioMEMS device
  6. Patients currently on inotropes
  7. English speaking

Exclusion Criteria

  1. Currently on dialysis
  2. Currently on hospice
  3. Have a heart transplant or left ventricular assist device
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    Cohort 1

    Stable outpatients without implantable devices

    Other: MouthLab Device

  • Other
    Cohort 2

    Stable outpatients with Boston Scientific pacemakers or defibrillators with Heart Logic capability

    Other: MouthLab Device

  • Other
    Cohort 3

    Stable outpatients with implantable CardioMEMS devices

    Other: MouthLab Device

Interventions

  • OtherMouthLab Device

    Use of MouthLab system

06

What researchers measure

Primary outcomes

  1. Evaluate trends of respiration rate per minute

    Respiration rate measured by breaths taken per minute

    Time frame: 6 months

  2. Aidar Questionnaire to Evaluate Patient Perception of Heart Failure

    The Aidar Questionnaire will be used to determine patient perception of severity of heart failure.

    Time frame: 6 months

  3. Evaluate trends of temperature measured in Fahrenheit

    Temperature

    Time frame: 6 months

  4. Evaluate trends of pulse rate per minute

    Pulse rate

    Time frame: 6 month

  5. Evaluating the P wave of electrocardiogram in milliseconds

    P wave on electrocardiogram will be measured to determine heart rhythm

    Time frame: 6 months

  6. Evaluating the QRS complex on electrocardiogram in milliseconds

    QRS complex will be measured to determine heart rhythm

    Time frame: 6 months

  7. Evaluating the T wave on electrocardiogram in milliseconds

    T wave will be measured to determine heart rhythm

    Time frame: 6 months

  8. Evaluate trends of blood pressure measured in mm/Hg

    Blood pressure

    Time frame: 6 months

  9. Evaluate trends of blood oxygen saturation (SpO2) in percentage

    blood oxygen saturation (SpO2)

    Time frame: 6 months

  10. Measuring FEV1 (Forced Expiratory Volume) in Liters

    Determining Lung Function

    Time frame: 6 months

  11. Measuring FVC (Forced Vital Capacity) in Liters

    Determining Lung Function

    Time frame: 6 months

  12. Measuring FEV1/FVC as a ratio

    Determining Lung Function

    Time frame: 6 months

  13. Measuring PEF (Peak Expiratory Flow) in Liters/second

    Determining Lung Function

    Time frame: 6 months

07

Study locations

1 site
  • WakeMed Health and Hospitals
    Raleigh, North Carolina 27610, United States
08

References and documents

Publications

  • Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659. No abstract available. Erratum In: Circulation. 2020 Jan 14;141(2):e33. doi: 10.1161/CIR.0000000000000746. PubMed 30700139 ↗
  • Writing Group Members; Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360. doi: 10.1161/CIR.0000000000000350. Epub 2015 Dec 16. No abstract available. Erratum In: Circulation. 2016 Apr 12;133(15):e599. doi: 10.1161/CIR.0000000000000409. PubMed 26673558 ↗
  • Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013 May;6(3):606-19. doi: 10.1161/HHF.0b013e318291329a. Epub 2013 Apr 24. PubMed 23616602 ↗
  • Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 17;75(10):1178-1195. doi: 10.1016/j.jacc.2019.12.059. PubMed 32164892 ↗
  • Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med. 1989 Mar-Apr;4(2):101-7. doi: 10.1007/BF02602348. PubMed 2709167 ↗
  • Garin O, Ferrer M, Pont A, Rue M, Kotzeva A, Wiklund I, Van Ganse E, Alonso J. Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res. 2009 Feb;18(1):71-85. doi: 10.1007/s11136-008-9416-4. Epub 2008 Dec 4. PubMed 19052916 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2022; primary completion for Oct 2022, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2021
First posted
Feb 17, 2021
StartEst.
Oct 2022
Primary completionEst.
Oct 2022
CompletionActual
Oct 20, 2022
Last update
Oct 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04757246
Lead sponsor
WakeMed Health and Hospitals
Responsible party
Stuart Russell, M.D. (Principal Investigator, WakeMed Health and Hospitals) — Principal investigator
First posted
Feb 17, 2021
Start date
Oct 2022 (estimated)
Primary completion
Oct 2022 (estimated)
Completion
Oct 20, 2022
Last update
Oct 24, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion